Floatz logo

Exendin-9,39

Type 2 Diabetes Mellitus

Mayo ClinicPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

142 Active assets in the Type 2 Diabetes Mellitus cohort.

Asset / SponsorPhaseRating
Liraglutide
RenJi Hospital
Phase 4BBB
Semaglutide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Cotadutide
AstraZeneca
Phase 2BBB
Dapagliflozin
Bhavya Bhavya, MD
Phase 4BBB
Exenatide
Vivani Medical, Inc
Phase 4BBB

View all 50 →

Same molecule, other indications

Exendin-9,39 is also rated in:

obesity disorderDormant
CCC
Indicative ·
53 / 100
View asset →
diabetes mellitusDormant
CC
Indicative ·
44 / 100
View asset →
morbid obesityDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →